Reviewing Heat Biologics (HTBX) and Its Competitors
Heat Biologics (NASDAQ: HTBX) is one of 288 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Heat Biologics to related businesses based on the strength of its dividends, risk, profitability, analyst recommendations, earnings, institutional ownership and valuation.
This table compares Heat Biologics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Heat Biologics Competitors||-4,766.74%||-354.83%||-43.39%|
Valuation & Earnings
This table compares Heat Biologics and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Heat Biologics||$777,132.00||-$11.53 million||-1.51|
|Heat Biologics Competitors||$464.68 million||$167.54 million||-6.57|
Heat Biologics’ peers have higher revenue and earnings than Heat Biologics. Heat Biologics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
8.7% of Heat Biologics shares are owned by institutional investors. Comparatively, 51.6% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 22.8% of Heat Biologics shares are owned by insiders. Comparatively, 17.4% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of current ratings and price targets for Heat Biologics and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Heat Biologics Competitors||1377||4466||12285||311||2.63|
Heat Biologics currently has a consensus target price of $2.13, indicating a potential upside of 243.24%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 34.46%. Given Heat Biologics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Heat Biologics is more favorable than its peers.
Risk & Volatility
Heat Biologics has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500. Comparatively, Heat Biologics’ peers have a beta of 6.57, suggesting that their average stock price is 557% more volatile than the S&P 500.
Heat Biologics Company Profile
Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.
Receive News & Stock Ratings for Heat Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics Inc. and related stocks with our FREE daily email newsletter.